Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immune Pharmaceuticals Inc.

www.immunepharmaceuticals.com

Latest From Immune Pharmaceuticals Inc.

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Pipeline Watch: Phase III Progress With Esaxerenone, Lusutrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Hepatic (Liver)
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • American Pharmed
  • EpiCept Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Immune Pharmaceuticals Inc.
  • Senior Management
  • Tony Fiorino, CMO & COO
    John Militello, VP, Fin.
  • Contact Info
  • Immune Pharmaceuticals Inc.
    Phone: (646) 440-9310
    430 East 29th St.
    Ste. 940
    New York, NY 10016
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register